Publications by authors named "Cesar Mendiola"

Claim this Profile
O
Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study.
Jacob Korach, Nicoletta Colombo, Cesar Mendiola, Frédéric Selle, Ignacio Dolado

J Surg Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Yolanda Garcia Garcia, Ana de Juan Ferré, Cesar Mendiola, Maria-Pilar Barretina-Ginesta, Lydia Gaba Garcia

Int J Gynecol Cancer· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer.
Katerin Rojas L, Lucía Trilla-Fuertes, Angelo Gámez-Pozo, Cristina Chiva, Juan Sepúlveda, César Mendiola

Ecancermedicalscience· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Ignace Vergote, Corneel Coens, Matthew Nankivell, Gunnar B Kristensen, Mahesh K B Parmar, Cesar Mendiola

Lancet Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study.
Frédéric Selle, Nicoletta Colombo, Jacob Korach, César Mendiola, Andres Cardona

Int J Gynecol Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Amit M Oza, Frédéric Selle, Irina Davidenko, Jacob Korach, Cesar Mendiola

Int J Gynecol Cancer· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer.
Miguel J Sotelo, Jose Angel García-Sáenz, Luis Manso, Fernando Moreno, Eva Ciruelos, Cesar Mendiola

J Cancer Res Ther· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.
Angelo Gámez-Pozo, Ramón M Pérez Carrión, Luis Manso, Carmen Crespo, Cesar Mendiola

PLoS One· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Luca Gianni, Urania Dafni, Richard D Gelber, Evandro Azambuja, Susanne Muehlbauer, Cesar Mendiola

Lancet Oncol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
Alfonso Sánchez-Muñoz, César Mendiola, Elisabeth Pérez-Ruiz, César A Rodríguez-Sánchez, José Miguel Jurado

Oncology· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Ignace Vergote, Claes G Tropé, Frédéric Amant, Gunnar B Kristensen, Tom Ehlen, Cesar Mendiola

N Engl J Med· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer.
Enrique González-Billalabeitia, Julia Calzas, Daniel Castellano, Cesar Mendiola, Susana Bezares

Breast J· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer.
José Pérez-Regadera, Alfonso Sánchez-Muñoz, Javier De-la-Cruz, Claudio Ballestín, David Lora, Cesar Mendiola

Int J Gynecol Cancer· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis.
César Mendiola, Ma Angeles Vaz

Clin Transl Oncol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer.
José Pérez-Regadera, Alfonso Sánchez-Muñoz, Javier De-la-Cruz, Claudio Ballestín, David Lora, Cesar Mendiola

Oncology· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis